...Monteleone. He declined to disclose how or when Nogra obtained rights to GED-0301. Nogra (formerly Giuliani S.p.A....

...GED-0301 to treat moderate to severe Crohn's disease (CD) and other gastrointestinal indications. Nogra (formerly Giuliani S.p.A....

...commercialize GED-0301 to treat moderate to severe Crohn's disease and other gastrointestinal indications. Nogra (formerly Giuliani S.p.A....

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...MMX technology from Cosmo Pharmaceuticals S.p.A. (SIX:COPN; Lainate, Italy). Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...while Mochida has exclusive rights in Japan from Shire. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...while Mochida has exclusive rights in Japan from Shire. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....

...and Holman wrote in their amicus brief. Michael Samardzija, counsel at law firm Bracewell & Giuliani...

...but the possibility is there," Meyers said. Michael Samardzija, counsel in law firm Bracewell & Giuliani's...

...so much more familiar with patent law." Michael Samardzija, counsel at law firm Bracewell & Giuliani...

...to the compound in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani S.p.A....